Dual-Energy X-Ray Absorptiometry Compared to Computed Tomography for Visceral Adiposity Assessment Among Gastrointestinal and Pancreatic Cancer Survivors.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 08 2019
08 08 2019
Historique:
received:
19
10
2018
accepted:
23
07
2019
entrez:
10
8
2019
pubmed:
10
8
2019
medline:
18
11
2020
Statut:
epublish
Résumé
Dual-energy x-ray absorptiometry (DXA) for visceral adipose tissue (VAT) assessment is used as an alternative to computed tomography (CT) for research purposes in apparently healthy and clinical populations. It is unknown whether DXA is comparable to CT among cancer survivors, especially in cases where VAT assessment may be affected by treatment history and side effects and become more challenging to assess, such as a history of surgical gastrointestinal resection and/or ascites. The purpose of this study was to determine the level of agreement between DXA and CT when assessing VAT area and volume among cancer survivors. One hundred Gastrointestinal and pancreatic cancer survivors underwent abdominal and pelvis CT and whole-body DXA within 48 hours. Bland-Altman analysis revealed that in women and men, DXA VAT-area estimates were larger and smaller, respectively, and was consistently smaller in estimates for VAT-volume. Correlations from linear regression analysis revealed statistically significant positive correlations between measurement methods. Overall, while DXA VAT estimates are highly correlated with CT VAT estimates, DXA estimates show substantial bias which indicates the two methods are not interchangeable in this population. Further research is warranted with a larger, more homogeneous sample to develop better estimates of the bias.
Identifiants
pubmed: 31395928
doi: 10.1038/s41598-019-48027-1
pii: 10.1038/s41598-019-48027-1
pmc: PMC6687706
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11500Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA057730
Pays : United States
Références
J Am Coll Cardiol. 2013 Sep 3;62(10):921-5
pubmed: 23850922
JAMA. 2014 Feb 26;311(8):806-14
pubmed: 24570244
Obesity (Silver Spring). 2012 May;20(5):1109-14
pubmed: 22240726
Am J Gastroenterol. 2010 Jan;105(1):178-87
pubmed: 19755965
J Clin Endocrinol Metab. 2015 Jan;100(1):227-34
pubmed: 25226289
J Lipid Res. 2009 Apr;50 Suppl:S395-9
pubmed: 19017614
Int J Obes Relat Metab Disord. 2002 Jul;26(7):984-93
pubmed: 12080454
PLoS One. 2017 Aug 31;12(8):e0183515
pubmed: 28859115
J Magn Reson Imaging. 2008 Sep;28(3):543-58
pubmed: 18777528
Obesity (Silver Spring). 2012 Jun;20(6):1313-8
pubmed: 22282048
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Int J Obes (Lond). 2016 Mar;40(3):514-23
pubmed: 26443342
Obesity (Silver Spring). 2007 Feb;15(2):370-6
pubmed: 17299110
J Gastroenterol Hepatol. 2008 Mar;23(3):411-7
pubmed: 17725596
Bone. 2006 Jun;38(6):935-42
pubmed: 16376161
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Obes Res. 2004 Oct;12(10):1698-701
pubmed: 15536234
Appl Physiol Nutr Metab. 2014 Jun;39(6):687-92
pubmed: 24869972
NMR Biomed. 2015 Dec;28(12):1747-53
pubmed: 26768490
Radiology. 2008 Jul;248(1):254-63
pubmed: 18566177
Radiology. 1984 Oct;153(1):189-94
pubmed: 6089263
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
J Clin Densitom. 2014 Jan-Mar;17(1):78-83
pubmed: 23603054
Br J Nutr. 2010 Aug;104(4):582-8
pubmed: 20370942
Diabetol Metab Syndr. 2011 Jun 22;3:12
pubmed: 21696633
PLoS One. 2012;7(12):e51042
pubmed: 23272086
Clin Cancer Res. 2005 May 15;11(10):3642-6
pubmed: 15897559
Arch Intern Med. 2009 Dec 14;169(22):2078-86
pubmed: 20008690
Int J Cancer. 2014 Nov 15;135(10):2273-81
pubmed: 24692064
Am J Clin Nutr. 1995 Feb;61(2):274-8
pubmed: 7840063
Diabetes Care. 2010 Jan;33(1):184-9
pubmed: 19837793
Ann Saudi Med. 2009 Sep-Oct;29(5):369-77
pubmed: 19700895